nach oben

Indian Journal of Otolaryngology and Head & Neck Surgery

Erschienen in:

11.01.2022 | Original Article

Circulating Vimentin Over-Expression in Patients with Oral Sub Mucosal Fibrosis and Oral Squamous Cell Carcinoma

verfasst von: Sadhna Aggarwal, Baldeep Singh, Suresh C. Sharma, Satya N. Das

Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Abstract

Oral squamous cell carcinoma (OSCC) is one of the most common (90%) types of oral carcinomas in the world. It is the 2nd most common and 3rd deadliest cancer in India. The lack of early detection marker is one of the major causes of worst prognosis. The vimentin belongs to intermediate filament family proteins which plays significant role in maintaining cellular integrity. Over-expression of vimentin has been widely reported in many epithelial cancers however the information regarding its prevalence in the oral cancers still needs further scientific intervention. The expression level of circulating vimentin protein in serum samples (n = 30) of oral submucous fibrosis (OSMF), OSCC patients and healthy controls were measured by performing ELISA. The serum level of vimentin was significantly higher in OSMF (p < 0.01) and OSCC (p < 0.003) patients as compared to healthy subjects. The circulating vimentin levels showed a gradual increase with increasing disease status (normal < OSMF < OSCC). Circulatory levels of vimentin may ba useful indicator of disease progression and as a suitable target for therapeutic intervention of oral submucous fibrosis and oral carcinoma.

IARC Inc(2020): India fact sheet 2020. 361: 2

Jerjes W, Upile T, Radhi H et al (2012) The effect of tobacco and alcohol and their reduction/cessation on mortality in oral cancer patients: Short communication. Head Neck Oncol 4:6. https://doi.org/10.1186/1758-3284-4-6CrossRef

Deleyiannis FWB, Thomas DB, Vaughan TL, Davis S (1996) Alcoholism: Independent predictor of survival in patients with head and neck cancer. J Natl Cancer Inst 88:542–549. https://doi.org/10.1093/jnci/88.8.542CrossRef

Silverman S (2001) Demographics and occurrence of oral and pharyngeal cancers: The outcomes, the trends, the challenge. J Am Dent Assoc 132:7S-11S. https://doi.org/10.14219/jada.archive.2001.0382CrossRef

Khanna NN, Srivastava PK, Khanna S, Das SN (1983) Intensive combination chemotherapy for cancer of the oral cavity. Cancer 52:790–793CrossRef

Aggarwal S, Devaraja K, Sharma SC, Das SN (2014) Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance. Clin Chim Acta 436:35–40. https://doi.org/10.1016/j.cca.2014.04.027CrossRef

Aggarwal S, Sharma SC, Das SN (2015) Galectin-1 and galectin-3: Plausible tumour markers for oral squamous cell carcinoma and suitable targets for screening high-risk population. Clin Chim Acta 442:13–21. https://doi.org/10.1016/j.cca.2014.12.038CrossRef

Ali FM, Patil A, Patil K, Prasant MC (2014) Oral submucous fibrosis and its dermatological relation. Indian Dermatol Online J 5:260–265. https://doi.org/10.4103/2229-5178.137772CrossRef

Bazarsad S, Zhang X, Kim KY et al (2017) Identification of a combined biomarker for malignant transformation in oral submucous fibrosis. J Oral Pathol Med 46:431–438. https://doi.org/10.1111/jop.12483CrossRef

10.

Messica Y, Laser-Azogui A, Volberg T et al (2017) The role of vimentin in regulating cell invasive migration in dense cultures of breast carcinoma cells. Nano Lett 17:6941–6948. https://doi.org/10.1021/acs.nanolett.7b03358CrossRef

11.

Satelli A, Li S (2011) Vimentin in cancer and its potential as a molecular target for cancer therapy. Cell Mol Life Sci 68:3033–3046. https://doi.org/10.1007/s00018-011-0735-1CrossRef

12.

Ivaska J, Pallari HM, Nevo J, Eriksson JE (2007) Novel functions of vimentin in cell adhesion, migration, and signalling. Exp Cell Res 313(10):2050–2062. https://doi.org/10.1016/j.yexcr.2007.03.040CrossRef

13.

Mor-Vaknin N, Punturieri A, Sitwala K, Markovitz DM (2003) Vimentin is secreted by activated macrophages. Nat Cell Biol 5:59–63. https://doi.org/10.1038/ncb898CrossRef

14.

Nieminen M, Henttinen T, Merinen M et al (2006) Vimentin function in lymphocyte adhesion and transcellular migration. Nat Cell Biol 8:156–162. https://doi.org/10.1038/ncb1355CrossRef

15.

Franke WW, Grund C et al (1982) Formation of cytoskeletal elements during mouse embryogenesis: III. primary mesenchymal cells and the first appearance of vimentin filaments. Differentiation 23:43–59. https://doi.org/10.1111/j.1432-0436.1982.tb01266.xCrossRef

16.

Terzi F, Henrion D, Colucci-Guyon E et al (1997) Reduction of renal mass is lethal in mice lacking vimentin: role of endothelin-nitric oxide imbalance. J Clin Invest 100:1520–1528. https://doi.org/10.1172/JCI119675CrossRef

17.

Eckes B, Colucci-Guyon E, Smola H et al (2000) Impaired wound healing in embryonic and adult mice lacking vimentin. J Cell Sci 113(1):2455–2462CrossRef

18.

Suprewicz L, Swoger M, Gupta S et al (2021) Vimentin binds to SARS-CoV-2 spike protein and antibodies targeting extracellular vimentin block in vitro uptake of SARS-CoV-2 virus-like particles. BioRxiv Prepr Serv Biol. https://doi.org/10.1101/2021.01.08.425793CrossRef

19.

Satelli A, Hu J, Xia X, Li S (2016) Potential function of exogenous vimentin on the activation of Wnt signaling pathway in cancer cells. J Cancer 7:1824–1832. https://doi.org/10.7150/jca.15622CrossRef

20.

Mahesh PP, Retnakumar RJ, Mundayoor S (2016) Downregulation of vimentin in macrophages infected with live Mycobacterium tuberculosis is mediated by reactive oxygen species. Sci Rep 6:1–12. https://doi.org/10.1038/srep21526CrossRef

21.

Huo Y, Zheng Z, Chen Y et al (2016) Downregulation of vimentin expression increased drug resistance in ovarian cancer cells. Oncotarget 7:45876–45888. https://doi.org/10.18632/oncotarget.9970CrossRef

22.

Chang Y-C, Tsai C-H, Tai K-W et al (2002) Elevated vimentin expression in buccal mucosal fibroblasts by arecoline in vitro as a possible pathogenesis for oral submucous fibrosis. Oral Oncol 38:425–430. https://doi.org/10.1016/s1368-8375(01)00083-5CrossRef

23.

Thota R, Aggarwal S, Chirom AS et al (2020) Serum survivin in oral submucosal fibrosis and squamous cell carcinoma Indian. J Otolaryngol Head Neck Surg. https://doi.org/10.1007/s12070-020-01980-0CrossRef

24.

Goldie KN, Wedig T, Mitra K et al (2007) Dissecting the 3-D structure of vimentin intermediate filaments by cryo-electron tomography. J Struct Biol 158:378–385. https://doi.org/10.1016/j.jsb.2006.12.007CrossRef

25.

Eriksson JE, He T, Trejo-Skalli AV et al (2004) Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci 117:919–932. https://doi.org/10.1242/jcs.00906CrossRef

26.

Turowski P, Myles T, Hemmings BA et al (1999) Vimentin dephosphorylation by protein phosphatase 2A is modulated by the targeting subunit B55. Mol Biol Cell 10:1997–2015. https://doi.org/10.1091/mbc.10.6.1997CrossRef

27.

Chaffer CL, Brennan JP, Slavin JL et al (2006) Mesenchymal-to-epithelial transition facilitates bladder cancer metastasis: role of fibroblast growth factor receptor-2. Cancer Res 66:11271–11278. https://doi.org/10.1158/0008-5472.CAN-06-2044CrossRef

28.

Ramos I, Stamatakis K, Oeste CL, Pérez-Sala D (2020) Vimentin as a multifaceted player and potential therapeutic target in viral infections. Int J Mol Sci 21:1–27. https://doi.org/10.3390/ijms21134675CrossRef

29.

Stevens HP, Nim ER et al (2013) The intermediate filament protein, vimentin, is a regulator of NOD2 activity. Gut 62:695–707. https://doi.org/10.1136/gutjnl-2011-301775CrossRef

30.

Da Q, Behymer M, Correa JI et al (2014) Platelet adhesion involves a novel interaction between vimentin and von Willebrand factor under high shear stress. Blood 123:2715–2721. https://doi.org/10.1182/blood-2013-10-530428CrossRef

31.

Lam FW, Da Q, Guillory B, Cruz MA (2018) Recombinant human vimentin binds to P-selectin and blocks neutrophil capture and rolling on platelets and endothelium. J Immunol 200:1718–1726. https://doi.org/10.4049/jimmunol.1700784CrossRef

32.

Aggarwal S, John S, Sapra L et al (2019) Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells, Cancer Chemother. Pharmacol 83:451–461. https://doi.org/10.1007/s00280-018-3746-xCrossRef

33.

Liu S, Liu L, Ye W et al (2016) High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in oral squamous cell carcinoma. Sci Rep 6:1–9. https://doi.org/10.1038/srep38834CrossRef

Titel: Circulating Vimentin Over-Expression in Patients with Oral Sub Mucosal Fibrosis and Oral Squamous Cell Carcinoma
verfasst von: Sadhna Aggarwal
Baldeep Singh
Suresh C. Sharma
Satya N. Das
Publikationsdatum: 11.01.2022
Verlag: Springer India
Erschienen in: Indian Journal of Otolaryngology and Head & Neck Surgery / Ausgabe 4/2022
Print ISSN: 2231-3796
Elektronische ISSN: 0973-7707
DOI: https://doi.org/10.1007/s12070-021-03018-5

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Circulating Vimentin Over-Expression in Patients with Oral Sub Mucosal Fibrosis and Oral Squamous Cell Carcinoma

Abstract

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2022

Comprehensive vestibular evaluation in patients with Otosclerosis: a case control study

Local Anaesthetic Nerve Blocks in Endoscopic Nasal and Sinus Surgery

Epidemiological, Clinical and Radiological Profile of Patients with Foreign Body Oesophagus: A Prospective Study

A Four Year Retrospective Study of the Pattern of Fungal Laryngitis in a Tertiary Voice Care Centre

Endoscopic Management of Malignant Tumors of Paranasal Sinus and Nasal Cavity: An Institutional Experience

Management of Orbital Floor Fractures: Our Experience in 10 Years

Neu im Fachgebiet HNO

Darf man die Behandlung eines Neonazis ablehnen?

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Nur selten Nachblutungen nach Abszesstonsillektomie

Rezidivierender Peritonsillarabszess nach Oralsex

Update HNO